To develop and conduct clinical trials aimed at improving the treatment and prevention of cancer with the ultimate goal of reducing morbidity and mortality from this disease.
The Canadian Cancer Trials Group is a cooperative oncology group which carries out clinical trials in cancer therapy, supportive care and prevention across Canada and internationally. It is one of the national programmes and networks of the Canadian Cancer Society Research Institute (CCSRI), and is supported by the Canadian Cancer Society (CCS).
InformationThe information contained in this website is intended for use by Canadian Cancer Trials Group members at participating centres.
Nivolumab after Combined Modality Therapy in High-Risk Anal Cancer
Nivolumab Ipilimumab in Patients with HyperMutated Cancers Detected in Blood (NIMBLe)
A Study of the Drugs CFI-402257 and Paclitaxel in Patients with Advanced Breast Cancer
Phase 3 RandOmized Study comparing PERioperative nivolumab vs observation in Renal Cell Carcinoma undergoing nephrectomy (PROSPER RCC)
Novel Therapeutics vs Azacitidine in Patients with AML or High Risk Myelodysplastic Syndrome, Aged 60 or Older (LEAP, Intergroup Less Intense AML Platform Trial)
Efficacy of the Addition of Inotuzumab Ozogamicin to Frontline Therapy in Young Adults with Precursor B-Cell ALL
Trimodality Therapy With/out Durvalumab to Treat Patients with Muscle-Invasive Bladder Cancer
Circulating Tumor DNA as a Predictive Marker for Response to Chemotherapy in Pts with Stage II Colon Ca
Elective Volume Adjusted De-Escalation Radiotherapy (EVADER) in Patients with Low-risk HPV-related Oropharyngeal SCC
A Phase I Master Protocol of Novel Combination Therapy for Patients with Relapsed or Refractory Aggressive B-Cell Lymphoma
MK-3475 for Triple Receptor-Negative Breast Cancer with >/= 1 cm Residual Invasive Cancer or Positive Lymph Nodes After Neoadjuvant Chemotherapy
A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently with Radiotherapy versus Radiotherapy Alone for Inflammatory Breast Cancer
Local Ablative Therapy For Hormone Sensitive Oligometastatic Prostate Cancer [PLATON]
INSIGNA: Firstline Immunotherapy alone or in Combination with Chemo in Induction/Maintenance or Post Progression in Adv NSCLC with Immunobiomarker SIGNature-driven Analysis